Elvitegravir Quad pill matches efavirenz and atazanavir combos
KS in Africa: people with low CD4 counts still at risk despite ART
Protease inhibitor not superior to NNRTI in sub-Saharan Africa
HIV brain impairment: who gets it, and why?
Cancers in people with HIV: who gets them, and which ones?
Circumcision reduces HIV incidence in Ugandan men and herpes prevalence in South Africans
Superinfection: second HIV infections happen as often as first ones
Novel integrase inhibitor dolutegravir still potent at 96 weeks
